A randomized double-blind, placebo-controlled trial of 60 subjects suffering from coronary heart disease and type 2 diabetes, with the treatment arm given magnesium 250 mg/Zn 150 mg for 12 weeks versus the control arm taking placebo, showed beneficial effects of decreased fasting plasma glucose (β −9.44 mg/dL, 95% CI −18.30, −0.57, p = 0.03) and insulin levels (β −1.37 uIU/mL, 95% CI −2.57, −0.18, p = 0.02) when co-supplemented [88]. This evidence concerns the gene INS and type 2 diabetes mellitus.